Identifying the molecular and cellular signature of cardiac dilation following myocardial infarction

Merry L. Lindsey, Yonggang Ma, Elizabeth R. Flynn, Michael D. Winniford, Michael E. Hall, Kristine Y. DeLeon-Pennell

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Establishing molecular and cellular indicators that reflect the extent of dilation of the left ventricle (LV) after myocardial infarction (MI) may improve diagnostic and prognostic capabilities. We queried the Mouse Heart Attack Research Tool (mHART) 1.0 for day 7 post-MI mice (age 3–9 months, untreated males and females) with serial echocardiographic data at days 0, 1, and 7 (n = 51). Mice were classified into two subgroups determined by a median fold change of 1.6 in end-diastolic dimensions (EDD) normalized to pre-MI values; n = 26 fell below (moderate; mean of 1.42 ± 0.01) and n = 25 fell above this cut-off (extreme; mean of 1.79 ± 0.01; p < 0.001 vs. moderate). Plasma proteomic profiling of 34 analytes measured at day 7 post-MI from male mice (n = 12 moderate and 12 extreme) were evaluated as the test dataset, and receiver operating curve (ROC) analysis was used to assess strength of biomarkers. Females (n = 6 moderate and 9 extreme) were used as the validation dataset. Both by t-test and characteristic (ROC) curve analysis, lower macrophage inflammatory protein-1 gamma (MIP-1γ), lymphotactin, and granulocyte chemotactic protein-2 (GCP-2) were identified as plasma indicators for dilation status (p < 0.05 for all). Macrophage numbers were decreased and complement C5, laminin 1, and Ccr8 gene levels were significantly higher in the LV infarcts of the extreme dilation group (p < 0.05 for all). A composite panel including plasma MIP-1γ, lymphotactin, and GCP-2, and LV infarct Ccr8 and macrophage numbers strongly mirrored LV dilation status (AUC = 0.92; p < 0.0001). Using the mHART 1.0 database, we determined that a failure to mount sufficient macrophage-mediated inflammation was indicative of exacerbated LV dilation.

Original languageEnglish (US)
Pages (from-to)1845-1852
Number of pages8
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1865
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Dilatation
Heart Ventricles
Myocardial Infarction
Chemokine CXCL6
Macrophage Inflammatory Proteins
Macrophages
Complement C5
Research
ROC Curve
Proteomics
Area Under Curve
Blood Proteins
Biomarkers
Databases
Inflammation
Genes
Datasets
lymphotactin

Keywords

  • Big data
  • Cardiovascular disease
  • Inflammation
  • LV dilation
  • Macrophage
  • Myocardial infarction
  • Proteomics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Identifying the molecular and cellular signature of cardiac dilation following myocardial infarction. / Lindsey, Merry L.; Ma, Yonggang; Flynn, Elizabeth R.; Winniford, Michael D.; Hall, Michael E.; DeLeon-Pennell, Kristine Y.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1865, No. 7, 01.07.2019, p. 1845-1852.

Research output: Contribution to journalArticle

Lindsey, Merry L. ; Ma, Yonggang ; Flynn, Elizabeth R. ; Winniford, Michael D. ; Hall, Michael E. ; DeLeon-Pennell, Kristine Y. / Identifying the molecular and cellular signature of cardiac dilation following myocardial infarction. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 2019 ; Vol. 1865, No. 7. pp. 1845-1852.
@article{19be0a3ddf6c4782a07e8fbebb10ed76,
title = "Identifying the molecular and cellular signature of cardiac dilation following myocardial infarction",
abstract = "Establishing molecular and cellular indicators that reflect the extent of dilation of the left ventricle (LV) after myocardial infarction (MI) may improve diagnostic and prognostic capabilities. We queried the Mouse Heart Attack Research Tool (mHART) 1.0 for day 7 post-MI mice (age 3–9 months, untreated males and females) with serial echocardiographic data at days 0, 1, and 7 (n = 51). Mice were classified into two subgroups determined by a median fold change of 1.6 in end-diastolic dimensions (EDD) normalized to pre-MI values; n = 26 fell below (moderate; mean of 1.42 ± 0.01) and n = 25 fell above this cut-off (extreme; mean of 1.79 ± 0.01; p < 0.001 vs. moderate). Plasma proteomic profiling of 34 analytes measured at day 7 post-MI from male mice (n = 12 moderate and 12 extreme) were evaluated as the test dataset, and receiver operating curve (ROC) analysis was used to assess strength of biomarkers. Females (n = 6 moderate and 9 extreme) were used as the validation dataset. Both by t-test and characteristic (ROC) curve analysis, lower macrophage inflammatory protein-1 gamma (MIP-1γ), lymphotactin, and granulocyte chemotactic protein-2 (GCP-2) were identified as plasma indicators for dilation status (p < 0.05 for all). Macrophage numbers were decreased and complement C5, laminin 1, and Ccr8 gene levels were significantly higher in the LV infarcts of the extreme dilation group (p < 0.05 for all). A composite panel including plasma MIP-1γ, lymphotactin, and GCP-2, and LV infarct Ccr8 and macrophage numbers strongly mirrored LV dilation status (AUC = 0.92; p < 0.0001). Using the mHART 1.0 database, we determined that a failure to mount sufficient macrophage-mediated inflammation was indicative of exacerbated LV dilation.",
keywords = "Big data, Cardiovascular disease, Inflammation, LV dilation, Macrophage, Myocardial infarction, Proteomics",
author = "Lindsey, {Merry L.} and Yonggang Ma and Flynn, {Elizabeth R.} and Winniford, {Michael D.} and Hall, {Michael E.} and DeLeon-Pennell, {Kristine Y.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.bbadis.2018.09.023",
language = "English (US)",
volume = "1865",
pages = "1845--1852",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Identifying the molecular and cellular signature of cardiac dilation following myocardial infarction

AU - Lindsey, Merry L.

AU - Ma, Yonggang

AU - Flynn, Elizabeth R.

AU - Winniford, Michael D.

AU - Hall, Michael E.

AU - DeLeon-Pennell, Kristine Y.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Establishing molecular and cellular indicators that reflect the extent of dilation of the left ventricle (LV) after myocardial infarction (MI) may improve diagnostic and prognostic capabilities. We queried the Mouse Heart Attack Research Tool (mHART) 1.0 for day 7 post-MI mice (age 3–9 months, untreated males and females) with serial echocardiographic data at days 0, 1, and 7 (n = 51). Mice were classified into two subgroups determined by a median fold change of 1.6 in end-diastolic dimensions (EDD) normalized to pre-MI values; n = 26 fell below (moderate; mean of 1.42 ± 0.01) and n = 25 fell above this cut-off (extreme; mean of 1.79 ± 0.01; p < 0.001 vs. moderate). Plasma proteomic profiling of 34 analytes measured at day 7 post-MI from male mice (n = 12 moderate and 12 extreme) were evaluated as the test dataset, and receiver operating curve (ROC) analysis was used to assess strength of biomarkers. Females (n = 6 moderate and 9 extreme) were used as the validation dataset. Both by t-test and characteristic (ROC) curve analysis, lower macrophage inflammatory protein-1 gamma (MIP-1γ), lymphotactin, and granulocyte chemotactic protein-2 (GCP-2) were identified as plasma indicators for dilation status (p < 0.05 for all). Macrophage numbers were decreased and complement C5, laminin 1, and Ccr8 gene levels were significantly higher in the LV infarcts of the extreme dilation group (p < 0.05 for all). A composite panel including plasma MIP-1γ, lymphotactin, and GCP-2, and LV infarct Ccr8 and macrophage numbers strongly mirrored LV dilation status (AUC = 0.92; p < 0.0001). Using the mHART 1.0 database, we determined that a failure to mount sufficient macrophage-mediated inflammation was indicative of exacerbated LV dilation.

AB - Establishing molecular and cellular indicators that reflect the extent of dilation of the left ventricle (LV) after myocardial infarction (MI) may improve diagnostic and prognostic capabilities. We queried the Mouse Heart Attack Research Tool (mHART) 1.0 for day 7 post-MI mice (age 3–9 months, untreated males and females) with serial echocardiographic data at days 0, 1, and 7 (n = 51). Mice were classified into two subgroups determined by a median fold change of 1.6 in end-diastolic dimensions (EDD) normalized to pre-MI values; n = 26 fell below (moderate; mean of 1.42 ± 0.01) and n = 25 fell above this cut-off (extreme; mean of 1.79 ± 0.01; p < 0.001 vs. moderate). Plasma proteomic profiling of 34 analytes measured at day 7 post-MI from male mice (n = 12 moderate and 12 extreme) were evaluated as the test dataset, and receiver operating curve (ROC) analysis was used to assess strength of biomarkers. Females (n = 6 moderate and 9 extreme) were used as the validation dataset. Both by t-test and characteristic (ROC) curve analysis, lower macrophage inflammatory protein-1 gamma (MIP-1γ), lymphotactin, and granulocyte chemotactic protein-2 (GCP-2) were identified as plasma indicators for dilation status (p < 0.05 for all). Macrophage numbers were decreased and complement C5, laminin 1, and Ccr8 gene levels were significantly higher in the LV infarcts of the extreme dilation group (p < 0.05 for all). A composite panel including plasma MIP-1γ, lymphotactin, and GCP-2, and LV infarct Ccr8 and macrophage numbers strongly mirrored LV dilation status (AUC = 0.92; p < 0.0001). Using the mHART 1.0 database, we determined that a failure to mount sufficient macrophage-mediated inflammation was indicative of exacerbated LV dilation.

KW - Big data

KW - Cardiovascular disease

KW - Inflammation

KW - LV dilation

KW - Macrophage

KW - Myocardial infarction

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=85054079920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054079920&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2018.09.023

DO - 10.1016/j.bbadis.2018.09.023

M3 - Article

C2 - 31109452

AN - SCOPUS:85054079920

VL - 1865

SP - 1845

EP - 1852

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 7

ER -